RA
ABVX

Royce & Associates’s Abivax ABVX Stock Holding History

Royce & Associates’s Portfolio ABVX Stock Details ABVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.01M Buy
+45,103
New +$5.1M 0.05% 477

Other funds holding ABVX

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
HI
Helikon Investments London, United Kingdom $3.35B AUM 55.08% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royce & Associates's ABVX Position: Q2 2026 in Review

Royce & Associates opened a new position in Abivax (ABVX) in Q2 2026: 45,103 shares worth $6.01M. The stake represents 0.05% of the portfolio and ranks #477 among its holdings.

302 funds tracked by Wall St. Rank hold ABVX as of Q2 2026.

  • Royce & Associates held 45,103 shares of Abivax worth $6.01M as of Q2 2026.
  • Abivax was a new Royce & Associates position in Q2 2026.
  • Abivax made up 0.05% of Royce & Associates's portfolio in Q2 2026, its #477 holding.
  • 302 funds tracked by Wall St. Rank held Abivax as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.